Fucoidan enhances the anti-tumor effect of anti-PD-1 immunotherapy by regulating gut microbiota

作者：H.-F. Li, Tieying Dong, Meng Tao, Haifeng Zhao, Tongtong Lan, Shiyu Yan, Xinyi Gong, Qilong Hou, Xuezhen Ma, Yang Song · 发表于：Food & Function · 年份：2024 · DOI：10.1039/d3fo04807a · 被引用次数：50 · 研究领域：Gut microbiota and health、Salivary Gland Disorders and Functions、Tryptophan and brain disorders

. Metabolomics further revealed that fucoidan may have reversed the metabolic disturbances induced by the breast cancer model through tryptophan metabolism and glycerophospholipid metabolism pathways, with the most significant increase in the content of short-chain fatty acids, especially acetic and butyric acids. These modulations improved the function of effector T cells and suppressed Treg cell production. Thus, our findings suggest that fucoidan combined with the anti-PD-1 monoclonal antibody may be a novel strategy to sensitize breast cancer patients to anti-PD-1 monoclonal antibody immunotherapy. Meanwhile, the gut microbiota might serve as a new biomarker to predict the anti-PD-1 monoclonal antibody response to breast cancer immunotherapy.